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Abstract 
We aim to elucidate the link between inherited thrombophilias and 
pregnancies complicated with ischemic placental diseases, in Turkish 
women. This is a case control study comprising 140 women with ischemic 
placental disease and 60 uncomplicated pregnant women. Parameters 
including haemoglobin, platelet count, uric acid, vitamin B12, folic acid, 
copper, homocysteine, plasminogen activator inhibitor-1, fibrinogen, protein 
S, protein C, activated protein C resistance values were significantly changed 
in women with ischemic placental disease when compared to those with 
normal pregnancies.  
The association between thrombophilia and ischemic pregnancy diseases is 
stronger than suggested previously. Furthermore, copper is selectively 
elevated in complicated pregnancies.  
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Introduction 
It has been suggested that maternal inherited thrombophilia may be 
associated with complications of pregnancy resulting in adverse outcomes 
(Pobinger I, 2005) based on studies, one of which reported that 65% of 
women with preeclampsia, intrauterine growth restriction, unexplained 
intrauterine fetal demise or placental abruption had thrombophilia with an 
odds ratio of 5.2% for some form of mutation (Kupferming, 1999). 
Consequences of thrombophilia including interference with trophoblast 
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differentiation, inadequate placentation or thrombosis of placental 
vasculature might be the factor triggering the biological and clinical 
manifestations of ischemic placental diseases (Kupferming, 1999; Kujovich, 
2004). The paper aims at to examine the magnitude of the association 
between inherited thrombophilia and pregnancy complicated with ischemic 
placental diseases (IPL) including preeclampsia (PE), intrauterine growth 
restriction (IUGR) and intrauterine fetal demise (IUFD).  
 
Material and methods 
Two hundred pregnant women who applied to Gazi University 
Medical School, Department of Obstetrics between October 2002 and 
November 2004 were categorized in the third trimester of their pregnancies 
into 3 groups. Group 1, group 2 and group 3 included 70 women with 
preeclampsia (PE) of whom 19 had IUGR, 2 had PLABR and 2 had IUFD, 
70 women normotensive but with other ischemic placental diseases (IPD) 
consisting of 48 cases of intrauterine growth restriction (IUGR) and 22 cases 
with intrauterine fetal demise (IUFD) of whom 3 patients also had abruptio 
placenta, and 60 normotensive normal pregnant controls without any 
complications, respectively.  
All women were personally informed about the objectives of the 
study and permission was taken from the local institutional committee. The 
clinical data and blood samples were collected prospectively, but laboratory 
workup and data evaluation were achieved retrospectively, without any 
intervention. Universal principles of Helsinki Declaration were applied in 
this non-biomedical study.  
 The inclusion criteria were nulliparity and having normal 50-gr 
glucose loading test, for all 3 groups. Having blood pressure equal or more 
than 140 / 90 mmHg (at least twice over a 6 hour interval), proteinuria (more 
than 0.3 gr / 24 hours or more than  +2 protein in a spot urine test) for group 
1 and ischemic placental disease other than PE for group 2. The exclusion 
criteria were multiparity and having preexisting essential hypertension, 
diabetes mellitus, liver, kidney or metabolic diseases, any history of current 
drug use excluding iron supplement, excessive physical activity, a history of 
recurrent miscarriage, personal and family history of thromboembolic 
disease for all of the cases. 
 In the normotensive pregnancy group, the women were examined 
every 2 to 3 weeks between 28 and 36 weeks and weekly thereafter, whereas 
the optimal frequency, timing of prenatal care visits and methods of 
evaluation including fetal movement counting, nonstress testing, biophysical 
profile assessment and doppler flow studies were carried out according to the 
needs and risk status of each woman and her fetus.  Additional ultrasound 
examinations following a routine one performed between 18 and 22 weeks 
European Scientific Journal   April 2014  edition vol.10, No.12   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
66 
were done according to the presence maternal or fetal indications. When 
severe PE, IUGR, IUFD or PLABR, induction of labor and early delivery, 
endangered health of the mother and the fetus either vaginally or by cesarean 
section was achieved. 
 Blood samples were taken upon admission to the hospital following 6 
hours of fasting for the following measurements; hemoglobin (Hb), 
hematocrit (Htc), platelet count (PLT), serum albumin (Alb), uric acid 
(UAC), creatinine (CR), copper (Cu), homocysteine (Hcy), vitamin B12 (vit 
B12), folic acid (FOA), fibrinogen (FBN), protein C (PC), protein S (PS), 
antitrombin III (AT III), activated protein C resistance (aPCR) and 
plasminogen activator inhibitor-1 (PAI-1). All tests were carried out at the 
central laboratory of the hospital except thrombophilia markers. Atomic 
Absorption Spectrometry to measure Cu and high performance liquid 
chromatography (HPLC) to measure Hcy was used.  
 For thrombophilia tests, 10 ml of whole blood was placed in EDTA 
vacutainer tubes, kept on ice and centrifuged at 2500 rpm for 10-30 minutes 
within 30 minutes, plasma carefully extracted and frozen to -70 °С and 
transferred to the laboratory of the hospital on dry ice.  The sample tubes 
were just numbered without any patient identification so that the laboratory 
could be blinded. Thrombophilia markers were investigated in the hospital‘s 
central genetic laboratory. The STA® - Staclot® APC-R kit was used for the 
assessment of the activated protein C resistance (aPC-R) in plasma. Plasma 
samples whose clotting times were ≥ 120 seconds, or < 120 seconds were 
considered to be aPCR negative, or aPCR positive respectively. Asserachrom 
(Diagnostica Stago, France) Elisa kit for PAI-1, STA LIATEST 
immunoturbidimetric assay kit for protein C & S, STA ® Antithrombin III 
assay were used. 
 The statistical analyses were conducted with the Statistical Package 
for the Social Sciences (SPSS/PC-11), SPSS Inc. Chicago Ill, and USA. All 
data was provided on an average + standard deviation basis. The statistical 
analysis of the differences between the patient and control groups for the 
parameters showing normal distribution (PC, aPCR, PAI-1) was done with a 
one sided variance analysis ―ANOVA‖. Multiple comparisons were carried 
out to distinguish the differences in the groups of the substantive data from 
the ANOVA one sided variance analysis by using the ―Bonferroni test‖. The 
―Kruskal-Wallis variance analysis‖ was used to make comparisons among 
the parameters that did not demonstrate normal distribution. When 
significant differences were found in parameters as a result of the Kruskal-
Wallis variance analysis, the WJ Canover Practical Nonparametric test was 
used to which group is different from the other group? The mean values of 
Hcy, Cu, PAI-1, PS, PC, AT III and aPCR in preeclamptic women blood 
samples are defined as abnormally high or as abnormally low if the measured 
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values are more than %95 or less than %5 of the average levels measured in 
the control group women respectively. The groups were then compared with 
the Pearson Chi-Square test. A value of p<0.05 was considered as 
statistically significant. 
  
Results 
 Pregnant women with PE (group I), other IPD (group 2) and 
normotensive control  (group 3) were at similar ages. While body weight and 
BMI values were higher in preeclamptics than in the control group (p = 
0.016). They were not different in-group 2 when compared to groups 1 & 3. 
The numbers of women who are smoking and / or drinking Turkish coffee 
were similar in all groups. (Table 1)  
 
 
Further, women with PE (group 1) had higher average systolic / 
diastolic blood pressure measurements than groups 2 & 3, as expected (p = 
0.001). The duration of pregnancy in women with IPD (groups 1 & 2) was 
shorter (median of 34.2 and 35.4 weeks, p = 0.018 and p= 0.001, 
respectively) as opposed to group 3. Women with PE (group 1) also 
delivered earlier than women with IPD (group 2) (p = 0.003). Birth weights 
and newborn Apgar scores were also lower in groups 1 & 2 in comparison to 
group 3 and also in-group 2 in comparison to group 1 & 3 (p = 0.001 within 
all groups). In other words, we encountered the lowest birth weight and 
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apgar scores in-group 2, which is an expected finding since this group 
included also the women with IUFD. (Table 2)  
Table 2. Clinical characteristics of women with preeclampsia, other
ischemic placental diseases and normal control groups (mean ± SD)
Apgar ( 5. minute) ⁫ 9* ±0.76 6* ± 4.6 10*  ± 0
Diastolic BP (mmHg) ⁪ 99*   ±12.17 65*  ± 8.77 67*  ± 8.89
Women (n)                            70                          70  60   
Preeclamptic
pregnancies
(Gr I)Parameter
Apgar ( 1. minute) ⁫ 8* ±1.44 6* ± 4.51 9*   ± 0.37
Birth weight (gr) ⁫ 2615* ± 667 2162*± 544 3128* ± 325
Gestational age (wks) ⁭ 34.2* ± 2.64 35.4*± 2.39 37.3* ± 2.26
Systolic BP (mmHg) ⁪ 162*   ±12.17 105* ±14.69       106*  ±17.38
*P = 0.001 differences between ⁪ Gr’s 1 & 2 and 1 & 3   ;    ⁭ Gr’s 1 & 2 and 2 & 3  ;  
⁫ Gr’s 1 & 2, 1 & 3 and 2 & 3
Other
complications
(Gr II)
Normal     
controls
(Gr III)
 
 
While there was not a single case in the control group, out of 70 
women with PE, 19 (%27) women revealed IUGR fetuses, additional 2 
(%2.85) had IUFD and 2 (%2.85) had PLABR. Group 2, on the other hand, 
consisted completely of IUGR, IUFD and PLABR but with no PE. Although 
both medical and / or surgical methods of induction of labor were applied 
more frequently in both groups 1 & 2 when compared with normal control 
cases (group 3) (p = 0.018 and p = 0.001, respectively). The most frequently 
induced group of all was the one with normotensive IPD as opposed to 
groups 1 & 3 (p = 0.003 & p = 0.001, respectively), with 40% rate. The 
mode of delivery was similar in all groups. Cesarean section rather than 
vaginal delivery was the preferred method in the whole study population 
regardless of whether they had complicated or normal pregnancies. (Table 3) 
 
European Scientific Journal   April 2014  edition vol.10, No.12   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
69 
 
Table 3. Labor characteristics and mode of delivery in  women
with preeclampsia, other ischemic placental diseases and normal 
control groups (mean ± SD)
n             %           n            %           n       %          p 
Women 70                            70              60
Induction of 
Labor ⁫ 13           18.6          28           40                2    3.3      0.001*
Vaginal
delivery 20           28.6          31           44.3  24        40         0.141
Cesarean
delivery 50           71.4          39           55.7  36        60         0.141
Preeclamptic Other Normal 
pregnancies complications controls
Parameter (Gr I)                    (Gr II)            (Gr III)                               
* ⁫  difference between Gr’s 1 & 2 (p = 0.003), 1 & 3 (p = 0.018) and 2 & 3 (p = 0.001)
 
Regarding the laboratory results, although Htc levels were similar in 
all groups. Group 2 revealed higher Hb levels than groups 1 & 3 (p = 0.013). 
PLT on the other hand, was lower only in women with PE (group 1) as 
opposed to groups 2 & 3 (p = 0.002). While serum Alb and CR levels were 
indifferent within the groups. UAC and Cu levels were higher in women 
with PE (group 1) (the highest of all) than groups 2 & 3 and also higher in 
group 2 than group 3 but lower than group 1 (p = 0.001 within all groups).  
Likewise vit B12 levels were significantly different between each group with 
the other (p = 0.001), the lowest being in group 1, then group 2 as compared 
to control cases. FOA, on the other hand, was lower in women with PE 
(group 1) (p = 0.001) in comparison to women with IPD (group 2) and the 
control group (group 3). The mean values of Htc, Alb and CR were similar in 
all groups.  (Table 4) 
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Table 4. Laboratory parameters of women with preeclampsia, other
ischemic placental diseases and normal control groups (mean ± SD)
Women (n)                    70                           70         60
Hemoglobin (gr/dl) ⁪ 11.79± 1.35 12.14±1.23* 11.48± 1.47  0.013*
Hematocrit (%)   34.99± 3.28        35.49±3.44    35.04± 3.10 0.842
Platelet ⁭ 198.4 ±61.2*      231.5 ±54.0 224.4 ±53.3  0.002*
Albumin (mg/dl)    3.36± 0.43          3.55±0.39      3.44± 0.19   0.292
Kreatinin (mg/dl)        0.68± 0.11           0.70±0.25      0.70± 0.09   0.181
Üric Asit (mg/dl) ⁫ 3.79± 1.42*           3.23±1.02*      3.06± 0.38* 0.001*
Vit B12 (pg/ml) ⁫ 223.8±95.1*  234.9 ±84.3*   276.8 ±69.8* 0.001*
Folic Asit (ng/ml) ⁭ 10.53± 4.11* 13.48± 6.36    11.32±5.40*   0.002*
Cupper (µgr/dl) ⁫ 210.9±56.5*    183.3 ±47.8*    121.2 ±25.0* 0.001*
Preeclamptic Other Normal 
pregnancies complications controls
Parameter (Gr I)                      (Gr II)          (Gr III)         p                       
*   ⁪ difference between Gr 2 and Gr’s 1 & 3 (p=0.013) ; ⁭ difference between Gr 1 and Gr’s 2 
& 3 (p=0.002) ; ⁫ difference between each group with the other (p=0.001)  
 
In terms of coagulation factors, while serum FBN, HCY, aPCR, PAI-
1 were elevated and PS was decreased significantly (p = 0.001 in all 
differences) both in women with PE and IPD (Gr 1 & 2) when compared 
with the levels measured in the control group. PE group also revealed 
increased serum levels of PAI-1 than the IPD group (p = 0.019) (Table 5).  
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Table 5. Thrombophilia markers and serum homocysteine levels in  
women with preeclampsia, other ischemic placental diseases and
normal control groups (mean ± SD)
Women (n)                      70                        70          60
FBN (mg/dL) ⁪ 422.2 ±85.5*     423.2 ±83.2* 327.4 ±66.6*    0.001 *
HCY (µmol/L) ⁪ 10.50± 3.6*     10.97± 3.26*    7.25± 2.44* 0.001*
Protein C (%) 101.6 ±18.3     103.2 ±20.3 109.7 ±16.8    0.825
Protein S (%) ⁪ 55.55±28.9* 53.64±27.35*   68.48±17.22* 0.001*
AT III (%) 87.14±21.46 89.75±19.59  90.15±13.08  0.740
PAI-1 (ng/dl) ⁪ ⁫ 84.06±32.35*  70.88±33.37* 30.53±12.14* 0.001*
aPCR (sec) ⁪ 121.4 ±33.2*     126.4 ±38.8*    99.2 ± 20.9* 0.001*
Preeclamptic Other Normal 
pregnancies complications controls
Parameter (Gr I)                   (Gr II)          (Gr III)         p                       
*  ⁪ difference between Gr 1 and Gr’s 2 & 3 (p=0.001) ;
⁫ difference between Gr 1 and Gr’s 2 (p=0.019)  
 
Table 6 reveals the cut off levels of each parameter and the 
percentage of women with abnormal test result in the PE & IPD patient 
groups. As seen from the data, Cu in 85.7 & 68.6%, PAI-1 in 77.1 & 60%, 
aPCR in 31.4 & 37.1%, Hcy in 28.6 & 44.3%, respectively, were elevated 
and PS in 52.9 & 57.1% respectively was suppressed in PE & IPD groups. In 
table 7, relative risk ratios of developing PE & IPD with abnormal 
thrombophilia markers, Hcy and Cu blood levels are demonstrated. Odds 
ratios for each parameter were as follows; Cu OR 114 & 41.45; PAI-1 OR 
64.12 & 28.50; PS OR 32.51& 38.66; aPCR OR 8.7 & 11.22; Hcy OR 7.6 & 
15.10, respectively.  
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Table 6. The cut off levels and the percentage of women with 
abnormal test results in in women with preeclampsia, other ischemic
placental diseases and normal control groups
n               %            n                %        n           %
Women 70                            70          60   
Protein S   <%48       37             52.9        40            57.1         2           3.3       0.001 
(%)            >%48       33             47.1        30        42.9       58         94.7 0.001
PAI-1 <58.37      16 22.9        28             40.0      57          95.0  0.001
(ng/dl) >58.37      54 77.1        42             60.0        3            5.0 0.001
aPCR <138.48      48 68.6        44 62.9       57         95.0       0.001
(sec) >138.48      22 31.4        26             37.1         3           5.0 0.001
HCY           <10.97      50             71.4        39         55.7       57         95.0       0.001
(µmol/L) >10.97      20             28.6        31             44.3  3           5.0       0.001
Copper <159.80     10             14.3        22             31.4 57         95.0      0.001
(µgr/dl) >159.80     60              85.7        48            68.6  3           5.0      0.001
Preeclamptic Other Normal 
pregnancies complications controls
Parameter (Gr I)                        (Gr II)     (Gr III)               p
P = 0.001  
 
Table 7. Likelihood ratios of developing preeclampsia and other
ischemic placental diseases with abnormal thrombophilia markers, 
homocysteine and copper blood levels
Cupper
HCY
aPCR
Protein S
64.12 17.6 - 232.5 28.50         8.12 - 100.34
32.51 7.36 - 143.64 38.66 8.74 - 171.04
8.7 2.4 - 30.88 11.22 3.19 - 39.50
7.6 2.1 - 27.1 15.10 4.31 - 52.87
114 29.8 - 435.4 41.45 11.68 - 147.01
PAI-1
Confidence
interval (CI)
Odds
Ratio (OR)
Parameter Odds
Ratio (OR)
Confidence
interval (CI)
Preeclampsia Ischemic Placental disease
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Conclusion 
Recent studies suggest that although ischemic placental diseases like 
preeclampsia, fetal growth restriction, intrauterine fetal demise and other 
similar complications of pregnancy may differ in their clinical 
manifestations, they may be considered as one disease process that clinically 
manifests itself in an underlying continuum of mild disease to more severe 
disease states as pregnancy approaches term (Norwitz, 2006). Many studies 
also indicated that several thrombophilias have a high prevalence in women 
with ischemic placental diseases (Pabinger, 2005; Kujovich, 2004). 
In our study, all of the pregnant women in both IPD and control 
groups were young and nulliparous with single fetuses, with no risk factors 
for and family history of PE (like personal history of chronic hypertension, 
diabetes mellitus, renal or any autoimmune diseases). Therefore, we studied 
a well-selected low risk group of pregnant women to minimize the 
confounding factors which might increase the risk of IPD‘s, namely PE, 
IUGR and IUFD to occur, other than thrombophilia. The mean ages of the 
pregnant women in all of our 3 groups were comparable.  While older age, in 
general has been blamed for elevated risk of not only PE, but also of IUFD, 
preterm birth and IUGR regardless of parity (Lisonkova, 2010). There are 
also publications claiming that chronologic age per se may not be a good 
predictor of pregnancy outcome (Scholl, 1992). It has also been argued that 
current evidence on the association between maternal age and perinatal 
outcome remains largely clouded by age-related confounding factors (Ales, 
1990). Therefore, it remains unclear how much maternal age itself 
contributes to poor pregnancy outcome rather than age-related co-morbidity. 
Our preeclamptic (Gr 1), but not the normotensive IUGR and IUFD patients 
(Gr 2) were overweight with an average BMI of above 25 (26.79 ± 4.42), 
when compared with the control group (24.83 ± 1.67, p < 0.05). High 
maternal BMI is associated with large number of pregnancy-related 
complications such as preeclampsia and eclampsia, presumably related to the 
presence of insulin resistance and associated endothelial disorder (Mbah, 
2010). Besides the well-known risks of developing gestational hypertension 
and diabetes, obese women are also exposed to the risks of stillbirth and 
composite adverse pregnancy outcome (Crane, 2013). Smoking habit, which 
is considered to be a preventive measure for PE but hazardous for IUGR and 
IUFD was comparable in all groups (Voigt, 2013; Engel, 2013). The data 
indicate that human adverse reproductive and developmental effects are 
produced by caffeine also (Christian, 2001). Caffeine consumption increases 
Hcy levels, which is a risk factor for adverse perinatal outcomes, such as 
IUGR and PE, by acting as a vitamin B6 antagonist (Shiraishi, 2013). 
Prevalence of PE was shown to be increase with daily consumption of tea 
(Wei, 2009) and also with more than four cups of coffee (Wergeland, 1997). 
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It has long been known that environmental influences, such as smoking, 
alcohol use, poor nutrition (Shu, 1995) and thrombophilic state (Franchi, 
2004) leading to placental thrombosis have causative roles in impaired fetal 
growth (Crane, 2013). 
Although the medical literature is full of reports suggesting that a 
significant percentage of IUGR and IUFD pregnancies exhibit thrombophilia 
(Kupferminc, 1999; Ofir, 2013) one can also encounter studies claiming just 
the opposite (Infante-Rivard, 2002). 
In the present study, 19 out of 70 of our patients (27%) in the PE 
group (Gr 1) and 48 out of 70 patients (69%) in other IPD group (Gr 2) were 
diagnosed to carry growth restricted fetuses and therefore, had to be 
delivered early (34 weeks) whereas not a single case of IUGR was 
encountered in the control group. Considering that group 1 had 2 and group 2 
had 22 cases of IUFD, one can imagine that at least some of these fetuses 
might have been growth restricted also during the earlier weeks of gestation. 
We recognize that thrombophilia; by causing intervillous thrombosis and 
consequent placental perfusion impairment could be the reason behind IUGR 
and also IUFD. This cascade may eventually result in PLABR. In our and 
other‘s series, PLABR was encountered only in thrombophilic cases but not 
in the normal control pregnant women groups (Ananth, 2010). The women in 
groups 1 & 2 in the present study, had shorter duration of pregnancy (34.2 & 
35.4 wks, respectively), lower birth weight (2615 & 2162 gr, respectively) 
and apgar scores at 1 / 5 minutes (8/9 & 6/6, respectively) when compared to 
the control group (37.3 wks, 3128 gr and 9/10, respectively). Considering 
that delivery of the fetus is the only effective treatment of PE, IUGR, IUFD 
and PLABR, preterm delivery to save the life of the mother and the fetuses 
in IPD explains the shorter duration of pregnancy, lower birth weight and 
lower apgar scores.  
An elevation in Hb or Htc is hypothesised to be the result of a 
combination of reduced plasma circulating volume and enhanced 
erythropoiesis because of underlying placental hypoxia (Troeger, 2006). A 
recent sudy even claimed that an Hb value below 11.0 g/dL would exclude 
the risk for severe PE to 100% (Soliman, 2012). In our series, although PE 
women had lower PLT counts and women with IUGR and IUFD had higher 
Hb levels than the other 2 groups. There was no case with anemia or 
thrombocytopenia in either one of the groups. Women 
with thrombocytopenia have been claimed to have higher rates of PE, 
HELLP syndrome, IUGR and IUFD, PLABR, labor induction, preterm 
deliveries and lower Apgar scores. Moreover, to reflect also the severity of 
the primary disease perhaps as a marker of perinatal complications (Parnas, 
2006).The value of serum Alb in pregnancy-complicated hypertension is a 
significant indicator of disease severity and can be regarded as an important 
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marker of poor prognosis of perinatal outcomes (Seong, 2010). On the 
contrary, none of the biochemical markers are sufficiently accurate to 
recommend their use as an indicator or predictor of IUGR or IUFD in routine 
clinical practice (Conde-Agudelo, 2013; Hui, 2012). 
Hyperuricaemia has been described commonly in PE pregnancies, 
often preceding the diagnosis of PE and historically was used as a diagnostic 
marker until proteinuria was preferred as a marker of maternal renal 
dysfunction. Fetuses exposed to hypoxia have been shown to have increased 
serum levels of purine metabolites which can cross into the maternal 
circulation to be degraded by maternal xanthine oxidase, explaining the 
relationship between hyperuricemia and fetal growth retardation (Kocijancic, 
2013). In a recent study, one standard deviation increase in serum UAC level 
was associated with 2.3-fold increased odds of progression to PE and 1.5-
fold increased odds of developing clinically significant adverse maternal or 
infant conditions irrespective of the progression to PE (Saugstad, 1975). 
Furthermore it has been claimed that hyperuricaemia in women with PE 
identifies a population prone to develop specifically maternal renal disease, 
small for gestational age (SGA) and preterm birth (Wu, 2012) and should be 
considered at least as important as proteinuria in predicting adverse outcome 
(Bellomo, 2011). The debate is still open whether UAC is a simple marker of 
disease or has a causal role in the development of PE and/or IUGR. Although 
serum UAC and CR are expected to be strongly interrelated, not all studies 
demonstrated both to be elevated (Homer, 2008). Including ours, perhaps 
due to the fact that serum CR may be a less sensitive marker of hypertensive 
disease in pregnancy.  
In the present study, we have demonstrated that our cases with IPD 
(Gr 1 & 2) as compared to controls had normal and comparable serum Alb 
and CR but significantly higher UAC levels, supporting the view that 
hyperuricemia might be a component of the IPD and predictor of maternal 
and fetal complications. 
There is considerable evidence concerning trace elements serum level 
changes associated with IPD‘s (Sarwar, 2013), possibly due to the oxidative 
stress following deprived placental perfusion and ischemia (Kontic-Vucinic, 
2006). Deficiency of Cu, which is an essential co-factor for the enzymes 
catalase, superoxide dismutase and cytochrome oxidase, can lead to a variety 
of vascular and nutritional disorders (Alebic-Juretic, 2005). There are some 
published studies that show statistically significant higher levels of Cu in the 
circulation of women with PE in comparison to healthy pregnant women 
(Alebic-Juretic, 2005; Serdar, 2006; Kumru, 2003). In others though, Cu 
serum levels are significantly higher both in healthy and pathological 
pregnancies (Katz, 2012; Frenzl, 2013) or even lower maternal serum 
concentrations of Cu have been described (Farzin, 2012). In another study, 
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IUGR cases showed higher magnesium, copper, and selenium concentrations 
in umbilical cord arterial sera and higher magnesium and selenium 
concentrations in placental tissue, but no significant differences appeared for 
the elements measured in maternal and umbilical cord venous sera (Osada, 
2002). 
In the present study, the serum Cu levels were significantly elevated 
both in groups 1 & 2 versus normal pregnant women, so much so that more 
than 86% of preeclamptic women and 69% of women with IUGR and IUFD 
revealed levels above the normal treshold.  As a matter of fact, the likelihood 
ratio of developing PE or IUGR and IUFD in women with elevated Cu levels 
was 114 and 41, respectively.  Although this finding is very stimulating, 
even intriguing, similar data have to be reproduced by others.   
Hyperhomocysteinemia is reported in women with PE and / or IUGR 
versus age-matched normotensive pregnant control subjects (Hogg, 2000). 
The levels of vit B12 and FOA were reported to be low in most (Acilmis, 
2011; Lachmeijer, 2001), as yet unchanged in in others as compared to 
control groups (Hogg, 2000; Gadhok, 2011). Recent studies revealed that 
increasing serum Hcy levels in pregnancies complicated with IUGR were 
accompanied by decreasing levels of serum FOA and vit B12 (Furness, 
2013). In the present study, both preeclamptic and IUGR patients also 
revealed higher Hcy and lower FOA and B12 levels in accord with the 
previous studies. In a review, the presence of high Hcy values increased the 
relative risk of IPD 1.32–3.2, while the RR reached 9.7 in primiparas and 6.9 
in obese patients (Powers, 1998). In our series, in primiparas, the likelihoods 
of development of PE and IUGR were found to be 7 times and 15 times 
higher, respectively in women with elevated Hcy serum levels. 
Hyperhomocysteinemia was encountered in %28 of women with PE and in 
44% of women with IUGR, in the present study. 
Hyperfibrinogenaemia is associated with systemic arterial and venous 
thromboembolism and therefore may contribute to placental vascular disease 
associated with obstetric complications (Pabinger, 2005; Kujovich, 2004). 
Fibrinogen was found to be significantly elevated above controls in our 
groups of PE and IUGR.  
The primary aim of this study was to explore the magnitute of the 
impact of inherited thrombophilia on IPD‘s among a pregnant group of 
Turkish women. In this study, since mutations in the factor V mutations 
(FVL) are related to activated protein C resistance (aCPR) and FVL is 
reported in about 90% of patients with aPCR in the general population 
(Bernardi, 1997) we measured aPCR as a marker. 
We have clearly demonstrated that FBN, Hcy, PAI-1 and aPCR 
values are higher and PS values are lower in women with PE, IUGR and 
IUFD, when compared to our normotensive normal pregnant control group 
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(Table 5). The percentages of women with abnormal test results in women 
with PE and IUGR & IUFD are 77 and 60% for PAI-1, 47 and 43% for 
protein S, 31 and 37% for aPCR, 29 and 44% for Hcy, respectively (Table 
6). Regarding the likelihood ratios of developing PE and IUGR & IUFD of 
women with abnormal blood levels of thrombophilia markers are  [OR 64 
and 28] for PAI-1; [OR 32 and 38] for PS; [OR 9 and 11] for aPCR and [OR 
7 and 15] for Hcy, respectively (Table 7). Among all the laboratory 
parameters that we studied in our research, serum Cu levels predicted both 
the PE and IUGR & IUFD, the most with an odds ratio of 114 and 41, 
respectively, which was found to be elevated in more than 85% of 
preeclamptic and 68% of women with IUGR & IUFD.  In contrast to some 
previous studies (Robertson, 2006), we did not find an increased frequency 
of supressed PC and AT III levels in women with PE as compared to control 
women. 
Several recent metaanalyses that have attempted to analyze the 
collective data have reported that pooled OR for associations between 
inherited thrombophilia and IPD are generally in the 1.0 to 2.5 range, 
indicating that thrombophilia may be only weakly associated with PE, if at 
all (Lin, 2005). Based on the results of this present study of ours, we claim 
that the association between thrombophilia and PE & IUGR & IUFD is 
stronger than suggested by the majority of publications in the medical 
literature. The most important of all, other than thrombophilia, Cu as an 
independant marker is selectively and remarkably elevated in women with 
complicated pregnancies as compared to normal pregnant women. If this 
finding can be reproduced by others and if serum Cu levels can be 
demonstrated to begin increasing in the first trimester before the symptoms 
and findings of IPD‘s exist, Cu could be a valuable tool to predict 
complications of pregnancy.  
The current case control study presents some limitations such as the 
study being done in a tertiary center, thereby not reflecting the general 
Turkish population and the small number of patients enrolled. Furthermore, 
prothrombin gene (G20210A) mutation was not tested in this study. One of 
the strengths is that potential confounding factors such as age, ethnicity, and 
systemic medical problems are overcome by the homogeneity of this study 
cohort and the participation of only primigravid women with no history of 
miscarriage. 
Whether the association between thrombophilia and IPD is causal or 
temporal, more specifically whether thrombophilia acts as a cofactor in the 
pathogenesis of these diseases or accelerates their course is, speculative. 
Lastly, even the strong association detected between PE, IUGR and IUFD 
and inherited thrombophilia in this study should not be considered as a 
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justification for screening for thrombophilia since there is no clear evidence 
that anticoagulation can prevent or improve the outcome.   
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